CTLA4 and hepatocellular carcinoma: For HCC, the incidences of severe irAEs for PD-1/PD-L1 blockade, CTLA-4 blockade, dual blockade of PD-L1/PD-L1 and CTLA-4, and ICIs combined with TKIs are 10–20%, ~25%, ~50%, and ~67%, respectively.